Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Enhanced MUC1 targeting chimeric antigen receptor and application thereof

A technology of chimeric antigen receptors and antigens, applied in the field of biomedicine, can solve problems such as tumor recurrence and drug resistance, and achieve the effect of improving activation activity and eliminating regulation

Inactive Publication Date: 2020-11-03
GUANGDONG ZHAOTAI INVIVO BIOMEDICINE CO LTD
View PDF9 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, CAR-T therapy always faces the problems of tumor recurrence and drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Enhanced MUC1 targeting chimeric antigen receptor and application thereof
  • Enhanced MUC1 targeting chimeric antigen receptor and application thereof
  • Enhanced MUC1 targeting chimeric antigen receptor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Construction of CAR Molecular Carrier

[0045] In this example, a chimeric antigen receptor αMUC1-CAR-T2 with an antigen-binding domain of an anti-MUC1 single-chain antibody and a signal transduction domain of 4-1BB, CD3ζ and TLR2 was constructed, the amino acid sequence of which is shown in SEQ ID NO: 2 Shown, the nucleic acid sequence is shown in SEQ ID NO:3;

[0046] Firstly, the coding gene of αMUC1-CAR-T2 chimeric antigen receptor (SEQ ID NO: 3) was gene-synthesized, and the restriction endonuclease Pme1 restriction site and its Protection base and restriction endonuclease Spe1 restriction site and its protection base;

[0047] The coding gene was double-digested with restriction endonucleases Pme1 and Spe1, incubated in a water bath at 37°C for 30 minutes, and the digested product containing sticky ends was recovered by agar gel electrophoresis, and ligated into a linear DNA that was also double-digested with Pme1 and Spe1. In the HopWPXLd-eGFP plasmid...

Embodiment 2

[0049] Example 2 lentiviral packaging

[0050] The lentiviral vector constructed in Example 1 was transferred into Escherichia coli, and positive single clones were selected for overnight culture, and the lentiviral vector was extracted using a plasmid extraction kit for virus packaging;

[0051] Use 293T cells for virus packaging and prepare the packaging system. The pWPXLd-expression plasmid includes a lentiviral vector containing the gene encoding αMUC1-CAR-T2 and a lentiviral vector containing the gene encoding αMUC1-CAR. The pWPXLd-eGFP plasmid does not contain CAR An empty vector encoding the gene;

[0052] The helper plasmid and the lentiviral vector with CAR molecule were simultaneously transfected into 293T cells, and the first and second viruses were harvested after 48h and 72h respectively, filtered and frozen at -80°C for use in immune cell transduction.

Embodiment 3

[0053] Example 3 T cell activation and lentiviral transfection

[0054]Mononuclear cells (PBMC) were isolated from adult peripheral blood, and total T cells were sorted out using a T cell sorting kit. After being stimulated in vitro by CD3 and CD28 antibodies for 24 hours, the overexpressed CAR molecule prepared in Example 2 was added. recombinant lentivirus;

[0055] After 12 hours of transduction, the T cells were centrifuged to change the medium; three days after the transduction, the content of GFP-positive cells was measured by flow cytometry, and the proportion of CAR-T was evaluated;

[0056] According to culture medium per milliliter 2 × 10 6 The CAR-T cells were cultured and expanded at a density of 3 cells to obtain αMUC1-CAR-T2-T, αMUC1-CAR-T and WT (transfected with blank control eGFP lentivirus) cells, and the cells were frozen ten days later until use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an enhanced MUC1 targeting chimeric antigen receptor and an application thereof. The chimeric antigen receptor comprises an antigen binding structural domain, a transmembrane structural domain and a signal transduction structural domain, wherein the antigen binding structural domain comprises an anti-MUC1 single-chain antibody and the signal transduction structural domain comprises 4-1BB, CD3 [zeta] and TLR2. The chimeric antigen receptor disclosed by the invention not only has a targeting effect on MUC1 positive tumor cells, but also can efficiently activate T cells, eliminate the immunosuppressive effect of regulatory T cells and promote the formation of memory T cells, and the constructed T cells for expressing the chimeric antigen receptor have remarkably enhanced tumor cell killing capacity.

Description

technical field [0001] The invention belongs to the technical field of biomedicine and relates to an enhanced chimeric antigen receptor targeting MUC1 and its application. Background technique [0002] Chimeric antigen receptor (chimeric antigen receptor, CAR) is composed of tumor-associated antigen binding region, extracellular hinge region, transmembrane region and intracellular signal transduction region. Usually, the antibody single-chain fragment variable (single chain fragment variable, scFv) contained in the CAR molecule has a specific binding effect on the tumor-associated antigen (tumor associated antigen, TAA). Cytoplasmic domain coupling. [0003] In recent years, with the development of tumor immunology theory and clinical technology, chimeric antigen receptor T-cell immunotherapy (CAR-T) has become one of the most promising tumor immunotherapies. At present, CAR-T cell therapy has been widely used in the treatment of B-cell malignancies. CAR-T cells targeting ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N5/10A61K39/00A61P35/00
CPCA61P35/00A61K39/00117C07K14/7051C07K16/18C07K2319/02C07K2319/03
Inventor 汤朝阳秦乐吴迪邓殷健吴海鹏王翠花冯世忠冯嘉昆其他发明人请求不公开姓名
Owner GUANGDONG ZHAOTAI INVIVO BIOMEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com